fda status bpc-157 tb-500 2025 or 2026 Evidence out, ideology in. The FDA's quiet peptide pivot has nothing to do with the data and everything to do with whose side the regulator is choosing. On April 15, 2026, the BPC-157 vs TB-500: Recovery Peptide
Description
People who do not match those groups, or who match a contraindication, should not use it without close clinician oversight and in some cases, should not use it at all
Key Takeaways BPC-157 is NOT FDA approved
A personalized energy plan built around you Compounded GLP-1 No insurance
Because AOD9604 does not stimulate IGF-1 production and lacks strong GH receptor agonism, it may present a safer alternative for long-term OA treatment [1]
